Bernhard Kiss
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
17.08.2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
17.08.2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction
Knüpfer S, Bachmann L, Kessels A, Miramontes E, Schneider M, Burkhard F, Kiss B, Pannek J, Wöllner J, Engeler D, Abt D, Mordasini L, Liechti M, Kessler T. Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction. BMC Urol 2014; 14:65.
13.08.2014Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction
13.08.2014BMC Urol 2014; 14:65
Knüpfer Stephanie C, Bachmann Lucas M, Kessels Alfons G, Miramontes Elena, Schneider Marc P, Burkhard Fiona C, Kiss Bernhard, Pannek Jürgen, Wöllner Jens, Engeler Daniel, Abt Dominik, Mordasini Livio, Liechti Martina D, Kessler Thomas M